Noble Financial Issues Positive Outlook for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Noble Financial lifted their Q2 2026 earnings estimates for Unicycive Therapeutics in a research report issued to clients and investors on Wednesday, July 1st. Noble Financial analyst R. Leboyer now expects that the company will post earnings per share of ($0.37) for the quarter, up from their prior estimate of ($0.77). Noble Financial currently has a “Outperform” rating and a $50.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.62) EPS and FY2027 earnings at $4.33 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its earnings results on Tuesday, May 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

A number of other brokerages also recently issued reports on UNCY. Weiss Ratings raised shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. B. Riley Financial reaffirmed a “buy” rating and issued a $22.00 target price on shares of Unicycive Therapeutics in a report on Tuesday. Wall Street Zen downgraded Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Benchmark cut their price target on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a report on Wednesday. Finally, HC Wainwright reduced their price target on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Unicycive Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $27.40.

Unicycive Therapeutics Trading Up 8.5%

UNCY opened at $5.73 on Friday. The firm’s 50 day simple moving average is $7.43 and its two-hundred day simple moving average is $6.81. The company has a market capitalization of $156.94 million, a PE ratio of -2.59 and a beta of 1.79. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $8.74.

Institutional Trading of Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics during the 2nd quarter valued at $55,000. JPMorgan Chase & Co. boosted its holdings in Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares during the period. Renaissance Technologies LLC bought a new stake in Unicycive Therapeutics during the first quarter valued at about $161,000. Bank of America Corp DE raised its holdings in Unicycive Therapeutics by 19,327.6% during the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after acquiring an additional 29,378 shares during the period. Finally, Quadrature Capital Ltd purchased a new position in shares of Unicycive Therapeutics in the fourth quarter valued at about $226,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics News Roundup

Here are the key news stories impacting Unicycive Therapeutics this week:

• Negative Sentiment: Investors are reacting to reports that Unicycive received a second FDA Complete Response Letter, with articles saying the agency cited third-party manufacturing deficiencies. That keeps regulatory uncertainty high and appears to be the main pressure on the stock. Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
• Negative Sentiment: Multiple law firms, including Kirby McInerney, Bragar Eagel & Squire, and Block & Leviton, announced securities-fraud investigations tied to the FDA update, which can add overhang and worsen investor sentiment. UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT
• Negative Sentiment: HC Wainwright and Noble Financial sharply reduced near-term earnings estimates for 2026 and 2027, signaling more caution around the company’s path to profitability even though both firms kept bullish ratings. MarketBeat UNCY analyst updates
• Neutral Sentiment: Despite the estimate cuts, analysts such as HC Wainwright and Noble Financial still have Buy/Outperform ratings and price targets well above the current share price, which may help limit downside if investors focus on longer-term commercialization potential. MarketBeat UNCY analyst updates

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.